Details of the Drug

General Information of Drug (ID: DMA8J1G)

Drug Name
Rifampin
Synonyms
Abrifam; Archidyn; Arficin; Arzide; Benemicin; Benemycin; Dipicin; Doloresum; Eremfat; Famcin; Fenampicin; RFP; RMP; Ramp; Rifa; Rifadin; Rifadine; Rifagen; Rifaldazin; Rifaldazine; Rifaldin; Rifam; Rifamor; Rifampicin; Rifampicina; Rifampicine; Rifampicinum; Rifamsolin; Rifaprodin; Rifcin; Rifinah; Rifobac; Rifoldin; Rifoldine; Riforal; Rimactan; Rimactane; Rimactazid; Rimactizid; Rimazid; Rimycin; Sinerdol; Tubocin; Rifamicin AMP; Rifampicin SV; Rifampicine [French]; Rifampin [USAN]; Rifamycin AMP; Ba 41166; AZT + Rifampin; BA-41166E; Ba 41166/E; DRG-0109; Dione 21-acetate; L-5103; L-5103 Lepetit; Piperine & Rifampicin; R-Cin; R/AMP; Reserpine & Rifampicin; Rifadin (TN); Rifadin I.V; Rifampicin & EEP; Rifampicin & Propolis; Rifampicina [INN-Spanish]; Rifampicinum [INN-Latin]; Rifampin (USP); Rimactan (TN); Rimactane (TN); Rimycin (TN); Sinerdol (TN); Tubocin (TN); Rifadin I.V.; Rifampicin (JP15/INN); Rifampicin[INN:BAN:JAN]; Rifadin, Rimactane, Rifampicin, Rifampin; 1-b]furan-21-yl acetate; 3-(((4-Methyl-1-piperazinyl)imino)-methyl)rifamycin; 3-(((4-Methyl-1-piperazinyl)imino)methyl)rifamycin SV; 3-(4-Methylpiperazinyliminomethyl)-rifamycin SV; 3-(4-Methylpiperazinyliminomethyl)rifamycin SV; 3-([(4-Methyl-1-piperazinyl)imino]methyl)rifamycin SV; 3-[(4-Methyl-1-piperazinyl)iminomethyl]rifamycin SV; 3-[[(4-Methyl-1-piperazinyl)imino]-methyl]rifamycin; 8-(((4-Methyl-1-piperazinyl)imino)methyl)rifamycin SV; 8-(4-Methylpiperazinyliminomethyl) rifamycin SV; 8-[[(4-Methyl-1-piperazinyl)imino[methyl]rifamycin; 8-[[(4-Methyl-1-piperazinyl)imino]methyl]rifamycin sv; 8-[[(4-Methylpiperazinyl)imino]methyl]rifamycin sv; 8CI)
Indication
Disease Entry ICD 11 Status REF
Tuberculosis 1B10-1B1Z Approved [1]
Therapeutic Class
Antituberculosis Agents
Drug Type
Small molecular drug
Structure
3D MOL is unavailable 2D MOL
#Ro5 Violations (Lipinski): 3 Molecular Weight (mw) 822.9
Topological Polar Surface Area (xlogp) 4.9
Rotatable Bond Count (rotbonds) 5
Hydrogen Bond Donor Count (hbonddonor) 6
Hydrogen Bond Acceptor Count (hbondacc) 15
ADMET Property
Absorption
The drug is well absorbed from the gastrointestinal tract [2]
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [3]
Bioavailability
70% of drug becomes completely available to its intended biological destination(s) [4]
Clearance
The drug present in the plasma can be removed from the body at the rate of 3.5 mL/min/kg [5]
Elimination
7% of drug is excreted from urine in the unchanged form [3]
Half-life
The concentration or amount of drug in body reduced by one-half in 3.35 +/- 0.66 hours [5]
Metabolism
The drug is metabolized via the hepatic [2]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 24.30248 micromolar/kg/day [6]
Unbound Fraction
The unbound fraction of drug in plasma is 0.2% [5]
Vd
Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 0.97 L/kg [5]
Chemical Identifiers
Formula
C43H58N4O12
IUPAC Name
[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate
Canonical SMILES
C[C@H]1/C=C/C=C(\\C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)/C=N/N5CCN(CC5)C)/C
InChI
InChI=1S/C43H58N4O12/c1-21-12-11-13-22(2)42(55)45-33-28(20-44-47-17-15-46(9)16-18-47)37(52)30-31(38(33)53)36(51)26(6)40-32(30)41(54)43(8,59-40)57-19-14-29(56-10)23(3)39(58-27(7)48)25(5)35(50)24(4)34(21)49/h11-14,19-21,23-25,29,34-35,39,49-53H,15-18H2,1-10H3,(H,45,55)/b12-11+,19-14+,22-13-,44-20+/t21-,23+,24+,25+,29-,34-,35+,39+,43-/m0/s1
InChIKey
JQXXHWHPUNPDRT-WLSIYKJHSA-N
Cross-matching ID
PubChem CID
135398735
ChEBI ID
CHEBI:28077
CAS Number
13292-46-1
TTD ID
D0G3DL
VARIDT ID
DR00196
ACDINA ID
D00591

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Bacterial RNA polymerase switch region (Bact RNAP-SR) TTIJ5EB NOUNIPROTAC Inhibitor [7], [8]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
Multidrug resistance-associated protein 2 (ABCC2) DTFI42L MRP2_HUMAN Substrate [9]
Breast cancer resistance protein (ABCG2) DTI7UX6 ABCG2_HUMAN Substrate [10]
Organic anion transporting polypeptide 1B1 (SLCO1B1) DT3D8F0 SO1B1_HUMAN Substrate [11]
Organic anion transporting polypeptide 1B3 (SLCO1B3) DT9C1TS SO1B3_HUMAN Substrate [12]
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [13]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Rifampin
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Pretomanid DMDYA31 Major Increased metabolism of Rifampin caused by Pretomanid mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [54]
Coadministration of a Drug Treating the Disease Different from Rifampin (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Sodium bicarbonate DMMU6BJ Moderate Decreased absorption of Rifampin due to altered gastric pH caused by Sodium bicarbonate. Acidosis [5C73] [55]
Clindamycin DM15HL8 Moderate Increased metabolism of Rifampin caused by Clindamycin mediated induction of CYP450 enzyme. Acne vulgaris [ED80] [56]
Pioglitazone DMKJ485 Moderate Increased metabolism of Rifampin caused by Pioglitazone mediated induction of CYP450 enzyme. Acute diabete complication [5A2Y] [57]
Glipizide DMZA5PQ Moderate Increased metabolism of Rifampin caused by Glipizide mediated induction of CYP450 enzyme. Acute diabete complication [5A2Y] [58]
Ivosidenib DM8S6T7 Major Increased metabolism of Rifampin caused by Ivosidenib mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [54]
Midostaurin DMI6E0R Major Increased metabolism of Rifampin caused by Midostaurin mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [59]
Oliceridine DM6MDCF Major Increased metabolism of Rifampin caused by Oliceridine mediated induction of CYP450 enzyme. Acute pain [MG31] [60]
Ivabradine DM0L594 Major Increased metabolism of Rifampin caused by Ivabradine mediated induction of CYP450 enzyme. Angina pectoris [BA40] [61]
Bepridil DM0RKS4 Major Increased metabolism of Rifampin caused by Bepridil mediated induction of CYP450 enzyme. Angina pectoris [BA40] [60]
Dronedarone DMA8FS5 Moderate Increased metabolism of Rifampin caused by Dronedarone mediated induction of CYP450 enzyme. Angina pectoris [BA40] [62]
Bedaquiline DM3906J Major Increased metabolism of Rifampin caused by Bedaquiline mediated induction of CYP450 enzyme. Antimicrobial drug resistance [MG50-MG52] [61]
Cilostazol DMZMSCT Moderate Increased metabolism of Rifampin caused by Cilostazol mediated induction of CYP450 enzyme. Arterial occlusive disease [BD40] [61]
Posaconazole DMUL5EW Moderate Increased metabolism of Rifampin caused by Posaconazole mediated induction of UGT. Aspergillosis [1F20] [61]
Aminophylline DML2NIB Moderate Increased metabolism of Rifampin caused by Aminophylline mediated induction of CYP450 enzyme. Asthma [CA23] [63]
Roflumilast DMPGHY8 Moderate Increased metabolism of Rifampin caused by Roflumilast mediated induction of CYP450 enzyme. Asthma [CA23] [64]
Clarithromycin DM4M1SG Moderate Decreased metabolism of Rifampin caused by Clarithromycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [65]
Rabeprazole DMMZXIW Moderate Increased metabolism of Rifampin caused by Rabeprazole mediated induction of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [61]
Ag-221 DMS0ZBI Moderate Decreased clearance of Rifampin due to the transporter inhibition by Ag-221. BCR-ABL1-negative chronic myeloid leukaemia [2A41] [66]
Cariprazine DMJYDVK Moderate Increased metabolism of Rifampin caused by Cariprazine mediated induction of CYP450 enzyme. Bipolar disorder [6A60] [54]
Erdafitinib DMI782S Major Increased metabolism of Rifampin caused by Erdafitinib mediated induction of CYP450 enzyme. Bladder cancer [2C94] [54]
Pexidartinib DMS2J0Z Major Decreased metabolism of Rifampin caused by Pexidartinib mediated inhibition of CYP450 enzyme. Bone/articular cartilage neoplasm [2F7B] [67]
Ixabepilone DM2OZ3G Moderate Increased metabolism of Rifampin caused by Ixabepilone mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [68]
HKI-272 DM6QOVN Major Increased metabolism of Rifampin caused by HKI-272 mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [66]
LY2835219 DM93VBZ Major Increased metabolism of Rifampin caused by LY2835219 mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [69]
Esterified estrogens DM9KZDO Moderate Increased metabolism of Rifampin caused by Esterified estrogens mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [70]
Tucatinib DMBESUA Major Increased metabolism of Rifampin caused by Tucatinib mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [54]
Palbociclib DMD7L94 Major Increased metabolism of Rifampin caused by Palbociclib mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [54]
Alpelisib DMEXMYK Major Increased metabolism of Rifampin caused by Alpelisib mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [61]
Quinestrol DMJ6H1Z Moderate Increased metabolism of Rifampin caused by Quinestrol mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [70]
Cabazitaxel DMPAZHC Moderate Increased metabolism of Rifampin caused by Cabazitaxel mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [71]
Bosutinib DMTI8YE Major Increased metabolism of Rifampin caused by Bosutinib mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [61]
Macitentan DMP79A1 Major Increased metabolism of Rifampin caused by Macitentan mediated induction of CYP450 enzyme. Cardiovascular disease [BA00-BE2Z] [72]
Doxercalciferol DM6FG1P Moderate Increased metabolism of Rifampin caused by Doxercalciferol mediated induction of CYP450 enzyme. Chronic kidney disease [GB61] [73]
PF-04449913 DMSB068 Major Increased metabolism of Rifampin caused by PF-04449913 mediated induction of CYP450 enzyme. Chronic myelomonocytic leukaemia [2A40] [54]
Revefenacin DMMP5SI Moderate Decreased clearance of Rifampin due to the transporter inhibition by Revefenacin. Chronic obstructive pulmonary disease [CA22] [74]
Dihydrocodeine DMB0FWL Moderate Increased metabolism of Rifampin caused by Dihydrocodeine mediated induction of CYP450 enzyme. Chronic pain [MG30] [75]
Anisindione DM2C48U Major Increased metabolism of Rifampin caused by Anisindione mediated induction of CYP450 enzyme. Coagulation defect [3B10] [76]
Regorafenib DMHSY1I Moderate Increased metabolism of Rifampin caused by Regorafenib mediated induction of CYP450 enzyme. Colorectal cancer [2B91] [54]
Intedanib DMSTA36 Major Increased metabolism of Rifampin caused by Intedanib mediated induction of CYP450 enzyme. Colorectal cancer [2B91] [77]
Drospirenone DM1A9W3 Major Increased metabolism of Rifampin caused by Drospirenone mediated induction of CYP450 enzyme. Contraceptive management [QA21] [78]
Levonorgestrel DM1DP7T Major Increased metabolism of Rifampin caused by Levonorgestrel mediated induction of CYP450 enzyme. Contraceptive management [QA21] [78]
Ulipristal DMBNI20 Moderate Increased metabolism of Rifampin caused by Ulipristal mediated induction of CYP450 enzyme. Contraceptive management [QA21] [61]
Halothane DM80OZ5 Major Increased risk of hepatotoxicity by the combination of Rifampin and Halothane. Corneal disease [9A76-9A78] [79]
Oxtriphylline DMLHSE3 Moderate Increased metabolism of Rifampin caused by Oxtriphylline mediated induction of CYP450 enzyme. Cough [MD12] [63]
Osilodrostat DMIJC9X Major Increased metabolism of Rifampin caused by Osilodrostat mediated induction of CYP450 enzyme. Cushing syndrome [5A70] [54]
Ivacaftor DMZC1HS Major Increased metabolism of Rifampin caused by Ivacaftor mediated induction of CYP450 enzyme. Cystic fibrosis [CA25] [66]
MK-8228 DMOB58Q Moderate Accelerated clearance of Rifampin due to the transporter induction by MK-8228. Cytomegaloviral disease [1D82] [66]
Rivaroxaban DMQMBZ1 Major Increased metabolism of Rifampin caused by Rivaroxaban mediated induction of CYP450 enzyme. Deep vein thrombosis [BD71] [77]
Sertraline DM0FB1J Moderate Increased risk of lowers seizure threshold by the combination of Rifampin and Sertraline. Depression [6A70-6A7Z] [80]
Vilazodone DM4LECQ Moderate Increased metabolism of Rifampin caused by Vilazodone mediated induction of CYP450 enzyme. Depression [6A70-6A7Z] [81]
Vortioxetine DM6F1PU Moderate Increased metabolism of Rifampin caused by Vortioxetine mediated induction of CYP450 enzyme. Depression [6A70-6A7Z] [82]
Escitalopram DMFK9HG Moderate Increased metabolism of Rifampin caused by Escitalopram mediated induction of CYP450 enzyme. Depression [6A70-6A7Z] [61]
OPC-34712 DMHG57U Moderate Increased metabolism of Rifampin caused by OPC-34712 mediated induction of CYP450 enzyme. Depression [6A70-6A7Z] [69]
Empagliflozin DMRF9YK Moderate Increased metabolism of Rifampin caused by Empagliflozin mediated induction of UGT. Diabetes mellitus [5A10] [66]
Polatuzumab vedotin DMF6Y0L Minor Increased metabolism of Rifampin caused by Polatuzumab vedotin mediated induction of CYP450 enzyme. Diffuse large B-cell lymphoma [2A81] [66]
[3H]estrone-3-sulphate DMGPF0N Moderate Increased metabolism of Rifampin caused by [3H]estrone-3-sulphate mediated induction of CYP450 enzyme. Discovery agent [N.A.] [70]
Ospemifene DMC4GEI Moderate Increased metabolism of Rifampin caused by Ospemifene mediated induction of CYP450 enzyme. Dyspareunia [GA12] [83]
Ingrezza DMVPLNC Major Increased metabolism of Rifampin caused by Ingrezza mediated induction of CYP450 enzyme. Dystonic disorder [8A02] [54]
Oestradiol valerate and dienogest DMZK0FQ Major Increased metabolism of Rifampin caused by Oestradiol valerate and dienogest mediated induction of CYP450 enzyme. Endometriosis [GA10] [78]
Stiripentol DMMSDOY Major Increased metabolism of Rifampin caused by Stiripentol mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [61]
Fosphenytoin DMOX3LB Moderate Increased metabolism of Rifampin caused by Fosphenytoin mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [84]
Brivaracetam DMSEPK8 Major Increased metabolism of Rifampin caused by Brivaracetam mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [61]
Clonazepam DMTO13J Minor Increased metabolism of Rifampin caused by Clonazepam mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [85]
Lacosamide DMVM6QR Minor Increased metabolism of Rifampin caused by Lacosamide mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [61]
Phenobarbital DMXZOCG Minor Increased metabolism of Rifampin caused by Phenobarbital mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [86]
Cannabidiol DM0659E Moderate Increased metabolism of Rifampin caused by Cannabidiol mediated induction of CYP450 enzyme. Epileptic encephalopathy [8A62] [61]
Praziquantel DMOU1PK Major Increased metabolism of Rifampin caused by Praziquantel mediated induction of CYP450 enzyme. Flatworm infection [1F70-1F86] [87]
Bay 80-6946 DMLOS5R Major Accelerated clearance of Rifampin due to the transporter induction by Bay 80-6946. Follicular lymphoma [2A80] [54]
Tazemetostat DMWP1BH Major Increased metabolism of Rifampin caused by Tazemetostat mediated induction of CYP450 enzyme. Follicular lymphoma [2A80] [88]
Mirabegron DMS1GYT Minor Increased metabolism of Rifampin caused by Mirabegron mediated induction of CYP450 enzyme. Functional bladder disorder [GC50] [89]
Itraconazole DMCR1MV Major Increased metabolism of Rifampin caused by Itraconazole mediated induction of CYP450 enzyme. Fungal infection [1F29-1F2F] [90]
Dexlansoprazole DM1DBV5 Moderate Increased metabolism of Rifampin caused by Dexlansoprazole mediated induction of CYP450 enzyme. Gastro-oesophageal reflux disease [DA22] [61]
Ripretinib DM958QB Major Increased metabolism of Rifampin caused by Ripretinib mediated induction of CYP450 enzyme. Gastrointestinal stromal tumour [2B5B] [91]
Sunitinib DMCBJSR Major Increased metabolism of Rifampin caused by Sunitinib mediated induction of CYP450 enzyme. Gastrointestinal stromal tumour [2B5B] [66]
Avapritinib DMK2GZX Major Increased metabolism of Rifampin caused by Avapritinib mediated induction of CYP450 enzyme. Gastrointestinal stromal tumour [2B5B] [61]
Carvedilol DMHTEAO Moderate Increased metabolism of Rifampin caused by Carvedilol mediated induction of CYP450 enzyme. Heart failure [BD10-BD1Z] [92]
Digitoxin DMWVIGP Moderate Increased metabolism of Rifampin caused by Digitoxin mediated induction of CYP450 enzyme. Heart failure [BD10-BD1Z] [93]
Boceprevir DMBSHMF Major Increased metabolism of Rifampin caused by Boceprevir mediated induction of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [94]
PSI-7977 DMLSUWZ Major Accelerated clearance of Rifampin due to the transporter induction by PSI-7977. Hepatitis virus infection [1E50-1E51] [61]
Simeprevir DMLUA9D Major Increased metabolism of Rifampin caused by Simeprevir mediated induction of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [77]
Telaprevir DMMRV29 Major Increased metabolism of Rifampin caused by Telaprevir mediated induction of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [95]
Daclatasvir DMSFK9V Major Increased metabolism of Rifampin caused by Daclatasvir mediated induction of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [61]
Brentuximab vedotin DMWLC57 Moderate Increased risk of hepatotoxicity by the combination of Rifampin and Brentuximab vedotin. Hodgkin lymphoma [2B30] [61]
MK-1439 DM215WE Major Increased metabolism of Rifampin caused by MK-1439 mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [96]
Fosamprenavir DM4W9B3 Major Increased metabolism of Rifampin caused by Fosamprenavir mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [97]
Cobicistat DM6L4H2 Major Increased metabolism of Rifampin caused by Cobicistat mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [66]
Dolutegravir DMCZGRE Major Increased metabolism of Rifampin caused by Dolutegravir mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [98]
Saquinavir DMG814N Major Increased metabolism of Rifampin caused by Saquinavir mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [99]
Elvitegravir DMG9B1U Major Increased metabolism of Rifampin caused by Elvitegravir mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [100]
Etravirine DMGV8QU Major Increased metabolism of Rifampin caused by Etravirine mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [54]
Rilpivirine DMJ0QOW Major Increased metabolism of Rifampin caused by Rilpivirine mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [101]
Darunavir DMN3GCH Major Increased metabolism of Rifampin caused by Darunavir mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [97]
Atazanavir DMSYRBX Major Increased metabolism of Rifampin caused by Atazanavir mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [97]
GSK1265744 DMT8J0I Major Increased metabolism of Rifampin caused by GSK1265744 mediated induction of UGT. Human immunodeficiency virus disease [1C60-1C62] [101]
Maraviroc DMTL94F Major Increased metabolism of Rifampin caused by Maraviroc mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [102]
Raltegravir DMYURI6 Major Increased metabolism of Rifampin caused by Raltegravir mediated induction of UGT. Human immunodeficiency virus disease [1C60-1C62] [77]
Bempedoic acid DM1CI9R Moderate Decreased clearance of Rifampin due to the transporter inhibition by Bempedoic acid. Hyper-lipoproteinaemia [5C80] [103]
Fluvastatin DM4MDJY Moderate Increased metabolism of Rifampin caused by Fluvastatin mediated induction of CYP450 enzyme. Hyper-lipoproteinaemia [5C80] [104]
Mipomersen DMGSRN1 Major Increased risk of hepatotoxicity by the combination of Rifampin and Mipomersen. Hyper-lipoproteinaemia [5C80] [105]
Teriflunomide DMQ2FKJ Major Increased risk of hepatotoxicity by the combination of Rifampin and Teriflunomide. Hyper-lipoproteinaemia [5C80] [77]
BMS-201038 DMQTAGO Major Increased risk of hepatotoxicity by the combination of Rifampin and BMS-201038. Hyper-lipoproteinaemia [5C80] [106]
Aliskiren DM1BV7W Minor Accelerated clearance of Rifampin due to the transporter induction by Aliskiren. Hypertension [BA00-BA04] [61]
Penbutolol DM4ES8F Moderate Increased metabolism of Rifampin caused by Penbutolol mediated induction of CYP450 enzyme. Hypertension [BA00-BA04] [92]
Levamlodipine DM92S6N Major Increased metabolism of Rifampin caused by Levamlodipine mediated induction of CYP450 enzyme. Hypertension [BA00-BA04] [60]
Tolvaptan DMIWFRL Major Increased metabolism of Rifampin caused by Tolvaptan mediated induction of CYP450 enzyme. Hypo-osmolality/hyponatraemia [5C72] [61]
Pirfenidone DM6VZFQ Moderate Increased metabolism of Rifampin caused by Pirfenidone mediated induction of CYP450 enzyme. Idiopathic interstitial pneumonitis [CB03] [61]
Febuxostat DMDEXQ0 Minor Increased metabolism of Rifampin caused by Febuxostat mediated induction of UGT. Inborn purine/pyrimidine/nucleotide metabolism error [5C55] [61]
Lesinurad DMUR64T Moderate Increased metabolism of Rifampin caused by Lesinurad mediated induction of CYP450 enzyme. Inborn purine/pyrimidine/nucleotide metabolism error [5C55] [54]
TP-434 DM5A31S Major Increased metabolism of Rifampin caused by TP-434 mediated induction of CYP450 enzyme. Infectious gastroenteritis/colitis [1A40] [54]
Suvorexant DM0E6S3 Major Increased metabolism of Rifampin caused by Suvorexant mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [54]
Melatonin DMKWFBT Minor Increased metabolism of Rifampin caused by Melatonin mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [66]
Tasimelteon DMLOQ1V Major Increased metabolism of Rifampin caused by Tasimelteon mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [54]
ITI-007 DMUQ1DO Major Increased metabolism of Rifampin caused by ITI-007 mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [107]
Quazepam DMY4D87 Minor Increased metabolism of Rifampin caused by Quazepam mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [85]
Estazolam DMZGXUM Minor Increased metabolism of Rifampin caused by Estazolam mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [85]
Eluxadoline DMYZ0P1 Major Decreased clearance of Rifampin due to the transporter inhibition by Eluxadoline. Irritable bowel syndrome [DD91] [61]
Pemigatinib DM819JF Major Increased metabolism of Rifampin caused by Pemigatinib mediated induction of CYP450 enzyme. Liver cancer [2C12] [54]
Crizotinib DM4F29C Major Increased metabolism of Rifampin caused by Crizotinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [66]
Brigatinib DM7W94S Major Increased metabolism of Rifampin caused by Brigatinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [66]
Ceritinib DMB920Z Major Increased metabolism of Rifampin caused by Ceritinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [54]
Lurbinectedin DMEFRTZ Major Decreased metabolism of Rifampin caused by Lurbinectedin mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [108]
PF-06463922 DMKM7EW Major Increased metabolism of Rifampin caused by PF-06463922 mediated induction of CYP450 enzyme. Lung cancer [2C25] [61]
Osimertinib DMRJLAT Major Increased metabolism of Rifampin caused by Osimertinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [66]
BIBW 2992 DMTKD7Q Moderate Accelerated clearance of Rifampin due to the transporter induction by BIBW 2992. Lung cancer [2C25] [77]
Pralsetinib DMWU0I2 Major Increased metabolism of Rifampin caused by Pralsetinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [54]
Capmatinib DMYCXKL Major Increased metabolism of Rifampin caused by Capmatinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [69]
Selpercatinib DMZR15V Major Increased metabolism of Rifampin caused by Selpercatinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [54]
Artemether DM48QOT Major Increased metabolism of Rifampin caused by Artemether mediated induction of CYP450 enzyme. Malaria [1F40-1F45] [66]
Artesunate DMR27C8 Moderate Increased metabolism of Rifampin caused by Artesunate mediated induction of UGT. Malaria [1F40-1F45] [109]
Hydroxychloroquine DMSIVND Moderate Increased metabolism of Rifampin caused by Hydroxychloroquine mediated induction of CYP450 enzyme. Malaria [1F40-1F45] [66]
Calaspargase pegol DMQZBXI Moderate Increased risk of hepatotoxicity by the combination of Rifampin and Calaspargase pegol. Malignant haematopoietic neoplasm [2B33] [110]
Idelalisib DM602WT Major Accelerated clearance of Rifampin due to the transporter induction by Idelalisib. Mature B-cell leukaemia [2A82] [54]
GDC-0199 DMH0QKA Major Increased metabolism of Rifampin caused by GDC-0199 mediated induction of CYP450 enzyme. Mature B-cell leukaemia [2A82] [111]
IPI-145 DMWA24P Major Increased metabolism of Rifampin caused by IPI-145 mediated induction of CYP450 enzyme. Mature B-cell leukaemia [2A82] [54]
Acalabrutinib DM7GCVW Major Increased metabolism of Rifampin caused by Acalabrutinib mediated induction of CYP450 enzyme. Mature B-cell lymphoma [2A85] [112]
Ibrutinib DMHZCPO Major Increased metabolism of Rifampin caused by Ibrutinib mediated induction of CYP450 enzyme. Mature B-cell lymphoma [2A85] [61]
Ponatinib DMYGJQO Moderate Increased metabolism of Rifampin caused by Ponatinib mediated induction of CYP450 enzyme. Mature B-cell lymphoma [2A85] [66]
Arry-162 DM1P6FR Moderate Increased metabolism of Rifampin caused by Arry-162 mediated induction of UGT. Melanoma [2C30] [61]
Vemurafenib DM62UG5 Major Increased metabolism of Rifampin caused by Vemurafenib mediated induction of CYP450 enzyme. Melanoma [2C30] [66]
Selumetinib DMC7W6R Major Increased metabolism of Rifampin caused by Selumetinib mediated induction of CYP450 enzyme. Melanoma [2C30] [113]
LGX818 DMNQXV8 Major Increased metabolism of Rifampin caused by LGX818 mediated induction of CYP450 enzyme. Melanoma [2C30] [114]
Ubrogepant DM749I3 Major Increased metabolism of Rifampin caused by Ubrogepant mediated induction of CYP450 enzyme. Migraine [8A80] [54]
Rimegepant DMHOAUG Major Increased metabolism of Rifampin caused by Rimegepant mediated induction of CYP450 enzyme. Migraine [8A80] [115]
Exjade DMHPRWG Moderate Increased metabolism of Rifampin caused by Exjade mediated induction of UGT. Mineral absorption/transport disorder [5C64] [66]
Lanthanum carbonate DMMJQSH Moderate Decreased absorption of Rifampin due to formation of complexes caused by Lanthanum carbonate. Mineral absorption/transport disorder [5C64] [77]
Dihydrotachysterol DMFB97P Moderate Increased metabolism of Rifampin caused by Dihydrotachysterol mediated induction of CYP450 enzyme. Mineral deficiency [5B5K] [73]
Flibanserin DM70DTN Major Increased metabolism of Rifampin caused by Flibanserin mediated induction of CYP450 enzyme. Mood disorder [6A60-6E23] [54]
Panobinostat DM58WKG Major Increased metabolism of Rifampin caused by Panobinostat mediated induction of CYP450 enzyme. Multiple myeloma [2A83] [61]
Siponimod DM2R86O Major Increased metabolism of Rifampin caused by Siponimod mediated induction of CYP450 enzyme. Multiple sclerosis [8A40] [66]
Ozanimod DMT6AM2 Major Increased metabolism of Rifampin caused by Ozanimod mediated induction of CYP450 enzyme. Multiple sclerosis [8A40] [116]
Deflazacort DMV0RNS Major Increased metabolism of Rifampin caused by Deflazacort mediated induction of CYP450 enzyme. Muscular dystrophy [8C70] [61]
Fedratinib DM4ZBK6 Major Increased metabolism of Rifampin caused by Fedratinib mediated induction of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [91]
Nilotinib DM7HXWT Major Increased metabolism of Rifampin caused by Nilotinib mediated induction of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [54]
Vorapaxar DMA16BR Major Increased metabolism of Rifampin caused by Vorapaxar mediated induction of CYP450 enzyme. Myocardial infarction [BA41-BA43] [54]
Rolapitant DM8XP26 Major Increased metabolism of Rifampin caused by Rolapitant mediated induction of CYP450 enzyme. Nausea/vomiting [MD90] [61]
Netupitant DMEKAYI Major Increased metabolism of Rifampin caused by Netupitant mediated induction of CYP450 enzyme. Nausea/vomiting [MD90] [66]
E-2007 DMJDYNQ Moderate Increased metabolism of Rifampin caused by E-2007 mediated induction of CYP450 enzyme. Neuropathy [8C0Z] [61]
Bupropion DM5PCS7 Moderate Increased metabolism of Rifampin caused by Bupropion mediated induction of CYP450 enzyme. Nicotine use disorder [6C4A] [61]
Entrectinib DMMPTLH Major Increased metabolism of Rifampin caused by Entrectinib mediated induction of CYP450 enzyme. Non-small cell lung cancer [2C25] [61]
Levomethadyl Acetate DM06HG5 Major Increased metabolism of Rifampin caused by Levomethadyl Acetate mediated induction of CYP450 enzyme. Opioid use disorder [6C43] [54]
S-297995 DM26IH8 Major Increased metabolism of Rifampin caused by S-297995 mediated induction of CYP450 enzyme. Opioid use disorder [6C43] [54]
Olaparib DM8QB1D Major Increased metabolism of Rifampin caused by Olaparib mediated induction of CYP450 enzyme. Ovarian cancer [2C73] [66]
Rucaparib DM9PVX8 Moderate Increased metabolism of Rifampin caused by Rucaparib mediated induction of CYP450 enzyme. Ovarian cancer [2C73] [54]
Istradefylline DM20VSK Major Increased metabolism of Rifampin caused by Istradefylline mediated induction of CYP450 enzyme. Parkinsonism [8A00] [54]
Pimavanserin DMR7IVC Moderate Increased metabolism of Rifampin caused by Pimavanserin mediated induction of CYP450 enzyme. Parkinsonism [8A00] [117]
Macimorelin DMQYJIR Moderate Increased metabolism of Rifampin caused by Macimorelin mediated induction of CYP450 enzyme. Pituitary gland disorder [5A60-5A61] [118]
Lefamulin DME6G97 Major Accelerated clearance of Rifampin due to the transporter induction by Lefamulin. Pneumonia [CA40] [54]
Ergonovine DM0VEC1 Moderate Increased metabolism of Rifampin caused by Ergonovine mediated induction of CYP450 enzyme. Postpartum haemorrhage [JA43] [66]
Lonafarnib DMGM2Z6 Major Increased metabolism of Rifampin caused by Lonafarnib mediated induction of CYP450 enzyme. Premature ageing appearance [LD2B] [54]
ABIRATERONE DM8V75C Major Increased metabolism of Rifampin caused by ABIRATERONE mediated induction of CYP450 enzyme. Prostate cancer [2C82] [69]
Enzalutamide DMGL19D Moderate Increased metabolism of Rifampin caused by Enzalutamide mediated induction of CYP450 enzyme. Prostate cancer [2C82] [118]
Relugolix DMK7IWL Major Accelerated clearance of Rifampin due to the transporter induction by Relugolix. Prostate cancer [2C82] [54]
Darolutamide DMV7YFT Major Accelerated clearance of Rifampin due to the transporter induction by Darolutamide. Prostate cancer [2C82] [69]
Silodosin DMJSBT6 Moderate Accelerated clearance of Rifampin due to the transporter induction by Silodosin. Prostate hyperplasia [GA90] [66]
Apremilast DMTWS9E Major Increased metabolism of Rifampin caused by Apremilast mediated induction of CYP450 enzyme. Psoriasis [EA90] [69]
Selexipag DMAHSU0 Moderate Increased metabolism of Rifampin caused by Selexipag mediated induction of CYP450 enzyme. Pulmonary hypertension [BB01] [61]
Riociguat DMXBLMP Moderate Increased metabolism of Rifampin caused by Riociguat mediated induction of CYP450 enzyme. Pulmonary hypertension [BB01] [119]
Everolimus DM8X2EH Major Accelerated clearance of Rifampin due to the transporter induction by Everolimus. Renal cell carcinoma [2C90] [77]
Axitinib DMGVH6N Major Increased metabolism of Rifampin caused by Axitinib mediated induction of CYP450 enzyme. Renal cell carcinoma [2C90] [120]
Temsirolimus DMS104F Major Increased metabolism of Rifampin caused by Temsirolimus mediated induction of CYP450 enzyme. Renal cell carcinoma [2C90] [66]
Upadacitinib DM32B5U Major Increased metabolism of Rifampin caused by Upadacitinib mediated induction of CYP450 enzyme. Rheumatoid arthritis [FA20] [54]
Tofacitinib DMBS370 Major Increased metabolism of Rifampin caused by Tofacitinib mediated induction of CYP450 enzyme. Rheumatoid arthritis [FA20] [66]
Dexamethasone DMMWZET Moderate Increased metabolism of Rifampin caused by Dexamethasone mediated induction of CYP450 enzyme. Rheumatoid arthritis [FA20] [121]
Leflunomide DMR8ONJ Major Increased risk of hepatotoxicity by the combination of Rifampin and Leflunomide. Rheumatoid arthritis [FA20] [66]
Quetiapine DM1N62C Major Increased metabolism of Rifampin caused by Quetiapine mediated induction of CYP450 enzyme. Schizophrenia [6A20] [122]
Aripiprazole DM3NUMH Moderate Increased metabolism of Rifampin caused by Aripiprazole mediated induction of CYP450 enzyme. Schizophrenia [6A20] [123]
Paliperidone DM7NPJS Moderate Accelerated clearance of Rifampin due to the transporter induction by Paliperidone. Schizophrenia [6A20] [66]
Avanafil DM75CXN Moderate Increased metabolism of Rifampin caused by Avanafil mediated induction of CYP450 enzyme. Sexual dysfunction [HA00-HA01] [69]
Voxelotor DMCS6M5 Major Increased metabolism of Rifampin caused by Voxelotor mediated induction of CYP450 enzyme. Sickle-cell disorder [3A51] [91]
Larotrectinib DM26CQR Major Accelerated clearance of Rifampin due to the transporter induction by Larotrectinib. Solid tumour/cancer [2A00-2F9Z] [66]
Docetaxel DMDI269 Moderate Increased metabolism of Rifampin caused by Docetaxel mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [124]
Trabectedin DMG3Y89 Major Increased metabolism of Rifampin caused by Trabectedin mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [61]
Armodafinil DMGB035 Moderate Increased metabolism of Rifampin caused by Armodafinil mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [125]
LEE011 DMMX75K Major Increased metabolism of Rifampin caused by LEE011 mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [54]
Vandetanib DMRICNP Moderate Increased metabolism of Rifampin caused by Vandetanib mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [126]
Taxol DMUOT9V Moderate Increased metabolism of Rifampin caused by Taxol mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [127]
Pitolisant DM8RFNJ Major Increased metabolism of Rifampin caused by Pitolisant mediated induction of CYP450 enzyme. Somnolence [MG42] [61]
Pomalidomide DMTGBAX Moderate Increased metabolism of Rifampin caused by Pomalidomide mediated induction of CYP450 enzyme. Systemic sclerosis [4A42] [54]
Fostamatinib DM6AUHV Major Increased metabolism of Rifampin caused by Fostamatinib mediated induction of CYP450 enzyme. Thrombocytopenia [3B64] [54]
Eltrombopag DMOGFIX Moderate Decreased clearance of Rifampin due to the transporter inhibition by Eltrombopag. Thrombocytopenia [3B64] [128]
As-1670542 DMV05SW Major Increased metabolism of Rifampin caused by As-1670542 mediated induction of CYP450 enzyme. Thrombocytopenia [3B64] [129]
Apixaban DM89JLN Major Increased metabolism of Rifampin caused by Apixaban mediated induction of CYP450 enzyme. Thrombosis [DB61-GB90] [61]
Brilinta DMBR01X Major Increased metabolism of Rifampin caused by Brilinta mediated induction of CYP450 enzyme. Thrombosis [DB61-GB90] [54]
Lenvatinib DMB1IU4 Minor Increased metabolism of Rifampin caused by Lenvatinib mediated induction of CYP450 enzyme. Thyroid cancer [2D10] [130]
Cabozantinib DMIYDT4 Major Increased metabolism of Rifampin caused by Cabozantinib mediated induction of CYP450 enzyme. Thyroid cancer [2D10] [131]
Tolbutamide DM02AWV Moderate Increased metabolism of Rifampin caused by Tolbutamide mediated induction of CYP450 enzyme. Type 2 diabetes mellitus [5A11] [58]
Saxagliptin DMGXENV Moderate Increased metabolism of Rifampin caused by Saxagliptin mediated induction of CYP450 enzyme. Type 2 diabetes mellitus [5A11] [132]
Linagliptin DMWFJTR Moderate Accelerated clearance of Rifampin due to the transporter induction by Linagliptin. Type 2 diabetes mellitus [5A11] [118]
Elagolix DMB2C0E Major Decreased clearance of Rifampin due to the transporter inhibition by Elagolix. Uterine fibroid [2E86] [133]
Betrixaban DM2C4RF Moderate Accelerated clearance of Rifampin due to the transporter induction by Betrixaban. Venous thromboembolism [BD72] [134]
Propafenone DMPIBJK Moderate Increased metabolism of Rifampin caused by Propafenone mediated induction of CYP450 enzyme. Ventricular tachyarrhythmia [BC71] [58]
Tocainide DMYNMDP Moderate Increased metabolism of Rifampin caused by Tocainide mediated induction of CYP450 enzyme. Ventricular tachyarrhythmia [BC71] [58]
⏷ Show the Full List of 212 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Allura red AC dye E00338 33258 Colorant
D&C red no. 28 E00491 6097185 Colorant
Docusate sodium E00563 23673837 Surfactant
FD&C blue no. 1 E00263 19700 Colorant
FD&C blue no. 2 E00446 2723854 Colorant
Isopropyl alcohol E00070 3776 Antimicrobial preservative; Solvent
Quinoline yellow WS E00309 24671 Colorant
Sodium benzoate E00432 517055 Antimicrobial preservative; lubricant
Sodium lauryl sulfate E00464 3423265 Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Ammonia E00007 222 Alkalizing agent
Butyl alcohol E00011 263 Flavoring agent; Solvent
Crospovidone E00626 Not Available Disintegrant
Ferrosoferric oxide E00231 14789 Colorant
Gelatin E00630 Not Available Other agent
Lactose monohydrate E00393 104938 Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate E00208 11177 lubricant
Potassium hydroxide E00233 14797 Alkalizing agent
Propylene glycol E00040 1030 Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Silicon dioxide E00670 Not Available Anticaking agent; Opacifying agent; Viscosity-controlling agent
Sodium hydroxide E00234 14798 Alkalizing agent
Talc E00520 16211421 Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
Sodium formaldehyde sulfoxylate E00570 23689980 Antioxidant
Cellulose microcrystalline E00698 Not Available Adsorbent; Suspending agent; Diluent
Shellac E00695 Not Available Coating agent; Film/membrane-forming agent; Microencapsulating agent; Modified-release agent
⏷ Show the Full List of 25 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Rifampicin 150 mg capsule 150 mg Oral Capsule Oral
Rifampicin 300 mg capsule 300 mg Oral Capsule Oral
Rifampin 300mg capsule 300mg Capsule Oral
Rifampin 600mg/10ml solution 600mg/10ml Solution Intravenous
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 Drugs used to treat Parkinson's disease, present status and future directions. CNS Neurol Disord Drug Targets. 2008 Oct;7(4):321-42.
2 FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
3 BDDCS applied to over 900 drugs
4 Critical Evaluation of Human Oral Bioavailability for Pharmaceutical Drugs by Using Various Cheminformatics Approaches
5 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
6 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
7 Bacillus subtilis tolerance of moderate concentrations of rifampin involves the sigma(B)-dependent general and multiple stress response. J Bacteriol. 2002 Jan;184(2):459-67.
8 Novel molecular targets for antimalarial drug development. Chem Biol Drug Des. 2008 Apr;71(4):287-97.
9 Expression and distribution of CYP3A genes, CYP2B22, and MDR1, MRP1, MRP2, LRP efflux transporters in brain of control and rifampicin-treated pigs. Mol Cell Biochem. 2010 Apr;337(1-2):133-43.
10 Arginine-482 is not essential for transport of antibiotics, primary bile acids and unconjugated sterols by the human breast cancer resistance protein (ABCG2). Biochem J. 2005 Jan 15;385(Pt 2):419-26.
11 Human organic anion transporting polypeptide-C (SLC21A6) is a major determinant of rifampin-mediated pregnane X receptor activation. J Pharmacol Exp Ther. 2003 Jan;304(1):223-8.
12 Interactions of rifamycin SV and rifampicin with organic anion uptake systems of human liver. Hepatology. 2002 Jul;36(1):164-72.
13 Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
14 Involvement of the drug transporters p glycoprotein and multidrug resistance-associated protein Mrp2 in telithromycin transport. Antimicrob Agents Chemother. 2006 Jan;50(1):80-7.
15 Dose-dependent disposition of methotrexate in Abcc2 and Abcc3 gene knockout murine models. Drug Metab Dispos. 2011 Nov;39(11):2155-61.
16 Mammalian multidrug-resistance proteins (MRPs). Essays Biochem. 2011 Sep 7;50(1):179-207.
17 Enhancing chemosensitivity in oral squamous cell carcinoma by lentivirus vector-mediated RNA interference targeting EGFR and MRP2. Oncol Lett. 2016 Sep;12(3):2107-2114.
18 Multidrug resistance associated protein 2 mediates transport of prostaglandin E2. Liver Int. 2006 Apr;26(3):362-8.
19 Lentivirus-mediated RNAi silencing targeting ABCC2 increasing the sensitivity of a human nasopharyngeal carcinoma cell line against cisplatin. J Transl Med. 2008 Oct 4;6:55.
20 Effect of acetaminophen on expression and activity of rat liver multidrug resistance-associated protein 2 and P-glycoprotein. Biochem Pharmacol. 2004 Aug 15;68(4):791-8.
21 Small intestinal efflux mediated by MRP2 and BCRP shifts sulfasalazine intestinal permeability from high to low, enabling its colonic targeting. Am J Physiol Gastrointest Liver Physiol. 2009 Aug;297(2):G371-7.
22 Delineating the contribution of secretory transporters in the efflux of etoposide using Madin-Darby canine kidney (MDCK) cells overexpressing P-glycoprotein (Pgp), multidrug resistance-associated protein (MRP1), and canalicular multispecific organic anion transporter (cMOAT). Drug Metab Dispos. 2002 Apr;30(4):457-63.
23 Multidrug Resistance-Associated Protein 2 (MRP2) Mediated Transport of Oxaliplatin-Derived Platinum in Membrane Vesicles. PLoS One. 2015 Jul 1;10(7):e0130727.
24 Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
25 MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents. Cancer Chemother Pharmacol. 2009 Jun;64(1):183-8.
26 Folate transporter expression decreases in the human placenta throughout pregnancy and in pre-eclampsia. Pregnancy Hypertens. 2012 Apr;2(2):123-31.
27 Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8.
28 Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol. 1994 Jul 19;48(2):287-92.
29 Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia. Ther Drug Monit. 2011 Apr;33(2):244-50.
30 Doxorubicin transport by RALBP1 and ABCG2 in lung and breast cancer. Int J Oncol. 2007 Mar;30(3):717-25.
31 Wild-type breast cancer resistance protein (BCRP/ABCG2) is a methotrexate polyglutamate transporter. Cancer Res. 2003 Sep 1;63(17):5538-43.
32 The effect of low pH on breast cancer resistance protein (ABCG2)-mediated transport of methotrexate, 7-hydroxymethotrexate, methotrexate diglutamate, folic acid, mitoxantrone, topotecan, and resveratrol in in vitro drug transport models. Mol Pharmacol. 2007 Jan;71(1):240-9.
33 Role of BCRP as a biomarker for predicting resistance to 5-fluorouracil in breast cancer. Cancer Chemother Pharmacol. 2009 May;63(6):1103-10.
34 Inhibiting the function of ABCB1 and ABCG2 by the EGFR tyrosine kinase inhibitor AG1478. Biochem Pharmacol. 2009 Mar 1;77(5):781-93.
35 Sterol transport by the human breast cancer resistance protein (ABCG2) expressed in Lactococcus lactis. J Biol Chem. 2003 Jun 6;278(23):20645-51.
36 The phytoestrogen genistein enhances multidrug resistance in breast cancer cell lines by translational regulation of ABC transporters. Cancer Lett. 2016 Jun 28;376(1):165-72.
37 Curcumin inhibits the activity of ABCG2/BCRP1, a multidrug resistance-linked ABC drug transporter in mice. Pharm Res. 2009 Feb;26(2):480-7.
38 Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump. Blood. 2004 Nov 1;104(9):2940-2.
39 Preclinical Mouse Models To Study Human OATP1B1- and OATP1B3-Mediated Drug-Drug Interactions in Vivo. Mol Pharm. 2015 Dec 7;12(12):4259-69.
40 Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol Rev. 2011 Mar;63(1):157-81.
41 Contribution of OATP1B1 and OATP1B3 to the disposition of sorafenib and sorafenib-glucuronide. Clin Cancer Res. 2013 Mar 15;19(6):1458-66.
42 Identification of drugs and drug metabolites as substrates of multidrug resistance protein 2 (MRP2) using triple-transfected MDCK-OATP1B1-UGT1A1-MRP2 cells. Br J Pharmacol. 2012 Mar;165(6):1836-1847.
43 The effect of SLCO1B1*15 on the disposition of pravastatin and pitavastatin is substrate dependent: the contribution of transporting activity changes by SLCO1B1*15. Pharmacogenet Genomics. 2008 May;18(5):424-33.
44 Influence of SLCO1B1, 1B3, 2B1 and ABCC2 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. Eur J Clin Pharmacol. 2007 Dec;63(12):1161-9.
45 Rifampicin alters atorvastatin plasma concentration on the basis of SLCO1B1 521T>C polymorphism. Clin Chim Acta. 2009 Jul;405(1-2):49-52.
46 FDA Drug Development and Drug Interactions
47 LST-2, a human liver-specific organic anion transporter, determines methotrexate sensitivity in gastrointestinal cancers. Gastroenterology. 2001 Jun;120(7):1689-99.
48 Effect of pregnane X receptor ligands on transport mediated by human OATP1B1 and OATP1B3. Eur J Pharmacol. 2008 Apr 14;584(1):57-65.
49 Influence of non-steroidal anti-inflammatory drugs on organic anion transporting polypeptide (OATP) 1B1- and OATP1B3-mediated drug transport. Drug Metab Dispos. 2011 Jun;39(6):1047-53.
50 Relevance of conserved lysine and arginine residues in transmembrane helices for the transport activity of organic anion transporting polypeptide 1B3. Br J Pharmacol. 2010 Feb 1;159(3):698-708.
51 Impact of OATP transporters on pharmacokinetics. Br J Pharmacol. 2009 Oct;158(3):693-705.
52 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
53 Novel agents in the management of Mycobacterium tuberculosis disease. Curr Med Chem. 2007;14(18):2000-8.
54 Patel S, Robinson R, Burk M "Hypertensive crisis associated with St. John's Wort." Am J Med 112 (2002): 507-8. [PMID: 11959071]
55 Product Information. Rifadin (rifampin). Hoechst Marion-Roussel Inc, Kansas City, MO.
56 Bernard A, Kermarrec G, Parize P, et.al "Dramatic reduction of clindamycin serum concentration in staphylococcal osteoarticular infection patients treated with the oral clindamycin-rifampicin combination." J Infect 71 (2015): 200-6. [PMID: 25936632]
57 Jaakkola T, Backman JT, Neuvonen M, Laitila J, Neuvonen PJ "Effect of rifampicin on the pharmacokinetics of pioglitazone." Br J Clin Pharmacol 61 (2006): 70-8. [PMID: 16390353]
58 Borcherding SM, Baciewicz AM, Self TH "Update on rifampin drug interactions." Arch Intern Med 152 (1992): 711-6. [PMID: 1558427]
59 Dutreix C, Munarini F, Lorenzo S, Roesel J, Wang Y "Investigation into CYP3A4-mediated drug-drug interactions on midostaurin in healthy volunteers." Cancer Chemother Pharmacol 72 (2013): 1223-34. [PMID: 24085261]
60 Product Information. Mycobutin (rifabutin). Pharmacia and Upjohn, Kalamazoo, MI.
61 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
62 Product Information. Multaq (dronedarone). sanofi-aventis , Bridgewater, NJ.
63 Dal Negro R, Turco P, Trevisan F, De Conti F "Rifampicin-isoniazid and delayed elimination of theophylline: a case report." Int J Clin Pharmacol Res 8 (1988): 275-7. [PMID: 3182118]
64 Nassr N, Huennemeyer A, Herzog R, et al. "Effects of rifampicin on the pharmacokinetics of roflumilast and roflumilast N-oxide in healthy subjects." Br J Clin Pharmacol 68 (2009): 580-7. [PMID: 19843061]
65 Apseloff G, Foulds G, LaBoy-Goral L, Willavize S, Vincent J "Comparison of azithromycin and clarithromycin in their interactions with rifabutin in healthy volunteers." J Clin Pharmacol 38 (1998): 830-5. [PMID: 9753212]
66 Cerner Multum, Inc. "Australian Product Information.".
67 Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
68 Product Information. Ixempra (ixabepilone). Bristol-Myers Squibb, Princeton, NJ.
69 Product Information. Kalydeco (ivacaftor). Vertex Pharmaceuticals, Cambridge, MA.
70 Back DJ, Breckenridge AM, Crawford FE, MacIver M, Orne ML, Rowe PH "Interindividual variation and drug interactions with hormonal steroid contraceptives." Drugs 21 (1981): 46-61. [PMID: 7009137]
71 Product Information. Jevtana (cabazitaxel). sanofi-aventis , Bridgewater, NJ.
72 Bruderer S, Aanismaa P, Homery MC, et al. "Effect of cyclosporine and rifampin on the pharmacokinetics of macitentan, a tissue-targeting dual endothelin receptor antagonist." AAPS J 14 (2012): 68-78. [PMID: 22189899]
73 Product Information. Hectorol (doxercalciferol). Genzyme Corporation, Cambridge, MA.
74 Product Information. Nexletol (bempedoic acid). Esperion Therapeutics, Ann Arbor, MI.
75 Caraco Y, Sheller J, Wood AJ "Pharmacogenetic determinants of codeine induction by rifampin: the impact on codeine's respiratory, psychomotor and miotic effects." J Pharmacol Exp Ther 281 (1997): 330-6. [PMID: 9103514]
76 Heimark LD, Gilbaldi M, Trager WF, et al "The mechanism of the warfarin-rifampin drug interaction in humans." Clin Pharmacol Ther 42 (1987): 388-94. [PMID: 3665337]
77 Canadian Pharmacists Association.
78 Back DJ, Breckenridge AM, Crawford F, et al. "The effect of rifampicin on norethisterone pharmacokinetics." Eur J Clin Pharmacol 15 (1979): 193-7. [PMID: 37091]
79 Most JA, Markle GB "A nearly fatal hepatotoxic reaction to rifampin after halothane anesthesia." Am J Surg 127 (1974): 593. [PMID: 4822375]
80 Product Information. Tegretol (carbamazepine). Novartis Pharmaceuticals, East Hanover, NJ.
81 Product Information. Viibryd (vilazodone). Trovis Pharmaceuticals LLC, New Haven, CT.
82 Product Information. Brintellix (vortioxetine). Takeda Pharmaceuticals America, Lincolnshire, IL.
83 Product Information. Osphena (ospemifene). Shionogi USA Inc, Florham Park, NJ.
84 Abajo FJ "Phenytoin interaction with rifampicin." Br Med J 297 (1988): 1048. [PMID: 3142625]
85 Ochs HR, Greenblatt DJ, Roberts GM, Dengler HJ "Diazepam interaction with antituberculosis drugs." Clin Pharmacol Ther 29 (1981): 671-8. [PMID: 7214796]
86 Richter E, Breimer DD, Zilly W "Disposition of hexobarbital in intra- and extrahepatic cholestasis in man and the influence of drug metabolism-inducing agents." Eur J Clin Pharmacol 17 (1980): 197-202. [PMID: 7363932]
87 Castro N, Medina R, Sotelo J, Jung H "Bioavailability of praziquantel increases with concomitant administration of food." Antimicrob Agents Chemother 44 (2000): 2903-4. [PMID: 10991886]
88 Product Information. Tazverik (tazemetostat). Epizyme, Inc, Cambridge, MA.
89 Product Information. Myrbetriq (mirabegron). Astellas Pharma US, Inc, Deerfield, IL.
90 Brass C, Galgiani JN, Blaschke TF, et al "Disposition of ketoconazole, an oral antifungal, in humans." Antimicrob Agents Chemother 21 (1982): 151-8. [PMID: 6282204]
91 Gunston GD, Mehta U "Potentially serious drug interactions with grapefruit juice." S Afr Med J 90 (2000): 41. [PMID: 10721388]
92 Kirch W, Rose I, Klingmann I, Pabst J, Ohnhaus EE "Interaction of bisoprolol with cimetidine and rifampicin." Eur J Clin Pharmacol 31 (1986): 59-62. [PMID: 2877885]
93 Boman G, Eliasson K, Odar-Cederlof I "Acute cardiac failure during treatment with digoxin--an interaction with rifampicin." Br J Clin Pharmacol 10 (1980): 89-90. [PMID: 7397060]
94 Product Information. Victrelis (boceprevir). Schering-Plough Corporation, Kenilworth, NJ.
95 Product Information. Incivek (telaprevir). Vertex Pharmaceuticals, Cambridge, MA.
96 Product Information. Pifeltro (doravirine). Merck &amp Company Inc, Whitehouse Station, NJ.
97 McGregor MM, Olliaro P, Wolmarans L, Mabuza B, Bredell M, Felten MK, Fourie PB "Efficacy and safety of rifabutin in the treatment of patients with newly diagnosed pulmonary tuberculosis." Am J Respir Crit Care Med 154 (1996): 1462-7. [PMID: 8912765]
98 Product Information. Dovato (dolutegravir-lamivudine). ViiV Healthcare, Research Triangle Park, NC.
99 Product Information. Invirase (saquinavir). Roche Laboratories, Nutley, NJ.
100 Product Information. Genvoya (cobicistat/elvitegravir/emtricitabine/tenofov). Gilead Sciences, Foster City, CA.
101 Cerner Multum, Inc. "Canadian Product Information.".
102 Product Information. Selzentry (maraviroc). Pfizer U.S. Pharmaceuticals Group, New York, NY.
103 Product Information. Mavyret (glecaprevir-pibrentasvir). Abbott Pharmaceutical, Abbott Park, IL.
104 Everett DW, Chando TJ, Didonato GC, Singhvi SM, Pan HY, Weinstein SH "Biotransformation of pravastatin sodium in humans." Drug Metab Dispos 19 (1991): 740-8. [PMID: 1680649]
105 Product Information. Kynamro (mipomersen). Genzyme Corporation, Cambridge, MA.
106 Product Information. Juxtapid (lomitapide). Aegerion Pharmaceuticals Inc, Cambridge, MA.
107 Product Information. Caplyta (lumateperone). Intra-Cellular Therapies, Inc., New York, NY.
108 Product Information. Xermelo (telotristat ethyl). Lexicon Pharmaceuticals, Inc., The Woodlands, TX.
109 Product Information. Artesunate (artesunate). Amivas, Frederick, MD.
110 Bodmer M, Sulz M, Stadlmann S, Droll A, Terracciano L, Krahenbuhl S "Fatal liver failure in an adult patient with acute lymphoblastic leukemia following treatment with L-asparaginase." Digestion 74 (2006): epub. [PMID: 16988508]
111 Cronk GA, Wheatley WB, Fellers GF, Albright H "The relationship of food intake to the absorption of potassium alpha-phenoxyethyl penicillin and potassium phenoxymethyl penicillin from the gastrointestinal tract." Am J Med Sci 240 (1960): 219-25. [PMID: 13812969]
112 Product Information. Calquence (acalabrutinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
113 Multum Information Services, Inc. Expert Review Panel.
114 Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
115 Product Information. Nurtec ODT (rimegepant). Biohaven Pharmaceuticals, New Haven, CT.
116 Product Information. Zeposia (ozanimod). Celgene Corporation, Summit, NJ.
117 Product Information. Nuplazid (pimavanserin). Accelis Pharma, East Windsor, NJ.
118 Product Information. Diabinese (chlorpropamide). Pfizer US Pharmaceuticals, New York, NY.
119 Product Information. Adempas (riociguat). Bayer Pharmaceutical Inc, West Haven, CT.
120 Pithavala YK, Tortorici M, Toh M, et al "Effect of rifampin on the pharmacokinetics of axitinib (AG-013736) in Japanese and Caucasian healthy volunteers." Cancer Chemother Pharmacol 65 (2010): 563-70. [PMID: 19603168]
121 Kyriazopoulou V, Parparousi O, Vagenakis AG "Rifampicin-induced adrenal crisis in Addisonian patients receiving corticosteroid replacement therapy." J Clin Endocrinol Metab 59 (1984): 1204-6. [PMID: 6490796]
122 Product Information. Seroquel (quetiapine). Zeneca Pharmaceuticals, Wilmington, DE.
123 Product Information. Abilify (aripiprazole). Bristol-Myers Squibb, Princeton, NJ.
124 Aronson JK, Grahame-Smith DG "Clinical pharmacology: adverse drug interactions." Br Med J 282 (1981): 288-91. [PMID: 6779990]
125 Product Information. Nuvigil (armodafinil). Cephalon Inc, West Chester, PA.
126 Martin P, Oliver S, Robertson J, Kennedy SJ, Read J, Duvauchelle T "Pharmacokinetic drug interactions with vandetanib during cadministration with rifampicin or itraconazole." Drugs R D 11 (2011): 37-51. [PMID: 21410294]
127 Jamis-Dow CA, Klecker RW, Katki AG, Collins JM "Metabolism of Taxol by human liver microsomes and effect of inhibitors (Meeting abstract)." Proc Annu Meet Am Assoc Cancer Res 34 (1993): a21981993.
128 Allred AJ, Bowen CJ, Park JW, et al. "Eltrombopag increases plasma rosuvastatin exposure in healthy volunteers." Br J Clin Pharmacol 72 (2011): 321-9. [PMID: 21434975]
129 Nomo, Zamora, Schuck, et al. "Pharmacokinetic/pharmacodynamic drug-drug interactions of avatrombopag when coadministered with dual or selective CYP2C9 and CYP3A interacting." PubMed 84 (2018): 1. [PMID: 29341245]
130 Product Information. Lenvima (lenvatinib). Eisai Inc, Woodcliff Lake, NJ.
131 Product Information. Cabometyx (cabozantinib). Exelixis Inc, S San Francisco, CA.
132 Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6. [PMID: 6953748]
133 Product Information. Orilissa (elagolix). AbbVie US LLC, North Chicago, IL.
134 Gelosa P, Castiglioni L, Tenconi M, et.al "Pharmacokinetic drug interactions of the non-vitamin K antagonist oral anticoagulants (NOACs)" Pharmacol Res 135 (2018): 60-79. [PMID: 30040996]